MicheletAMowlaMAmo-BrownBARodriguezNCavarettaM.Missed doses, missed opportunities: readmission due to GLP-1RA interruption inspires algorithms to improve reinitiation of therapy at discharge. Hosp Pharm. Published online 2025. doi:10.1177/00185787251372054
2.
BelančićAKresovićATroskot DijanM.Glucagon-like peptide-1 receptor agonists in the era of COVID-19: friend or foe?Clin Obes. 2021;11(2):e12439. doi:10.1111/cob.12439
3.
BelančićA.Obesity treatment beyond the scale: clinical reflections on obesity management and anti-obesity medicines. Basic Clin Pharmacol Toxicol. Published online 2025. Forthcoming.
4.
BelančićAAl-SallamiHS.Spotlight commentary: changes in pharmacokinetics following significant weight loss. Br J Clin Pharmacol. 2025;91(3):678-680. doi:10.1111/bcp.16401
5.
RaičevićBBBelančićAMirkovićNJankovićSM.Analysis of reporting trends of serious adverse events associated with anti-obesity drugs. Pharmacol Res Perspect. 2025;13(2):e70080. doi:10.1002/prp2.70080
6.
RiederMBelančićA.Past, present and future of drug safety: editorial. Br J Clin Pharmacol. 2024;90(8):1760-1762. doi:10.1111/bcp.16140
